The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms Biobank II; FINGO_HHU
- 10 Jun 2017 Biomarkers information updated
- 21 Jul 2015 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
- 21 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.